{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:23:04Z","timestamp":1787674984602,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04213-5","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:56:34Z","timestamp":1787673394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early anatomical rescue after switching to aflibercept 8\u00a0mg in faricimab-refractory neovascular AMD"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7505-4079","authenticated-orcid":false,"given":"Woohyok","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"4213_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116","journal-title":"Lancet Glob Health"},{"key":"4213_CR2","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST et al (2020) Age-related macular degeneration preferred practice pattern. Ophthalmology 127:P1\u2013P65","journal-title":"Ophthalmology"},{"issue":"20","key":"4213_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GA, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897\u20131908","journal-title":"N Engl J Med"},{"key":"4213_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"4213_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW (2021) Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res 82:100906","journal-title":"Prog Retin Eye Res"},{"key":"4213_CR6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857\u20131867","journal-title":"Drug Des Devel Ther"},{"key":"4213_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740","journal-title":"Lancet"},{"key":"4213_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology 131:914\u2013926","journal-title":"Ophthalmology"},{"key":"4213_CR9","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF et al (2023) Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond) 37:3282\u20133289","journal-title":"Eye (Lond)"},{"key":"4213_CR10","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20146 month results. Eye (Lond) 37:3574\u20133581","journal-title":"Eye (Lond)"},{"key":"4213_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Horiguchi E, Kawano K et al (2024) Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 262:43\u201351","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4213_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS et al (2024) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152","journal-title":"Lancet"},{"key":"4213_CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ophtha.2024.03.021","volume":"132","author":"JF Korobelnik","year":"2025","unstructured":"Korobelnik JF, Lanzetta P, Leal S et al (2025) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: 96-week results from the randomized phase 3 PULSAR trial. Ophthalmology 132:47\u201356","journal-title":"Ophthalmology"},{"key":"4213_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K et al (2023) Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol 141:834\u2013842","journal-title":"JAMA Ophthalmol"},{"key":"4213_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051416","volume":"15","author":"D Veritti","year":"2023","unstructured":"Veritti D, Sarao V, Di Bin F et al (2023) Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics 15:1416","journal-title":"Pharmaceutics"},{"key":"4213_CR16","first-page":"512","volume":"143","author":"WK Lee","year":"2025","unstructured":"Lee WK, Wong TY, Chen SJ et al (2025) Aflibercept 8 mg in polypoidal choroidal vasculopathy: post hoc analysis of the PULSAR randomized clinical trial. JAMA Ophthalmol 143:512\u2013520","journal-title":"JAMA Ophthalmol"},{"key":"4213_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","volume":"9","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GCS, Mohan N et al (2025) Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina 9:756\u2013766","journal-title":"Ophthalmol Retina"},{"key":"4213_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3928\/23258160-20241205-01","volume":"56","author":"B Momenaei","year":"2025","unstructured":"Momenaei B, Yonekawa Y, Abril P et al (2025) Switching to aflibercept 8 mg in neovascular age-related macular degeneration with prior faricimab exposure. Ophthalmic Surg Lasers Imaging Retina 56:206\u2013211","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4213_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01323-2","author":"CMG Cheung","year":"2026","unstructured":"Cheung CMG, Kikushima W, Teo KYC (2026) Initial experiences of switching to aflibercept 8 mg for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Ophthalmol Ther. https:\/\/doi.org\/10.1007\/s40123-026-01323-2","journal-title":"Ophthalmol Ther"},{"key":"4213_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology 127:616\u2013636","journal-title":"Ophthalmology"},{"key":"4213_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE et al (2023) Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol 17:1287\u20131293","journal-title":"Clin Ophthalmol"},{"key":"4213_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/bjo.2011.204685","volume":"96","author":"JL Gasperini","year":"2012","unstructured":"Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14\u201320","journal-title":"Br J Ophthalmol"},{"key":"4213_CR23","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y et al (2019) Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol 257:2559\u20132569","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4213_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G et al (2025) Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina 9:22\u201330","journal-title":"Ophthalmol Retina"},{"key":"4213_CR25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","volume":"262","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Rizzato A et al (2024) Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol 262:1151\u20131159","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04213-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04213-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04213-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:56:36Z","timestamp":1787673396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04213-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04213-5","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no relevant financial or conflict of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board (IRB approval number: P01-202601-01-030) and conducted in accordance with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"345"}}